ReviewFrontiers in cellular neuroscience2026
Cognitive and neurodevelopmental outcomes in spinal muscular atrophy: a scoping review.
Review in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal muscular atrophy (SMA) has traditionally been described as a motor neuron disorder; however, increasing evidence suggests a broader neurodevelopmental involvement, particularly in the era of disease-modifying therapies. As survival and motor outcomes improve, cognitive and behavioral trajectories have become clinically relevant but remain inconsistently characterized. To systematically synthesize current evidence on cognitive and neurodevelopmental outcomes in children and adults with SMA, with particular focus on differences across phenotypes and therapeutic eras. A scoping review was conducted including observational studies, clinical cohorts, and case series reporting cognitive, language, behavioral, or executive outcomes in individuals with SMA. Studies were analyzed qualitatively with attention to disease severity, age, and treatment status. Twenty-three studies were included. Global intellectual functioning was generally preserved, particularly in SMA types II and III. Nevertheless, selective vulnerabilities were frequently reported in processing speed, executive functioning, and language development. Behavioral and socio-emotional challenges were described in pediatric populations. Neurodevelopmental outcomes in early-onset SMA showed substantial heterogeneity, ranging from global developmental delay to relatively preserved cognitive trajectories, especially in pre-symptomatically treated patients. Methodological variability and motor-related testing limitations were common across studies. Cognitive functioning in SMA appears largely preserved in milder phenotypes but domain-specific vulnerabilities in processing speed, working memory, and language are consistently identified across phenotype groups and represent clinically relevant targets for monitoring and intervention. Systematic neurodevelopmental monitoring and standardized assessment protocols are needed to better define long-term outcomes as treatment modifies disease trajectories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.